Welcome to our dedicated page for INVVY news (Ticker: INVVY), a resource for investors and traders seeking the latest updates and insights on INVVY stock.
About Indivior PLC
Indivior PLC (symbol: INVVY) is a globally recognized pharmaceutical company dedicated to transforming the treatment landscape for substance use disorders (SUD) and serious mental health conditions. Headquartered in Richmond, Virginia, USA, Indivior operates across 37 countries and employs over 1,000 professionals. The company's mission centers on providing evidence-based treatment options to address the chronic and co-occurring conditions of SUD, aiming to shift the global perception of addiction from a crisis to a treatable chronic disease.
Core Business and Expertise
Indivior specializes in developing and commercializing innovative medications that target opioid addiction, overdose reversal, and other substance-related disorders. Its portfolio includes a range of products designed to address both acute and long-term challenges associated with SUD. A notable product is OPVEE®, an intranasal nalmefene spray approved for the emergency treatment of opioid overdoses. This product exemplifies Indivior's focus on rapid-acting solutions to combat the opioid crisis, particularly in cases involving synthetic opioids like fentanyl. Additionally, the company is expanding its pipeline to include treatments for alcohol use disorder and cannabis use disorder, further broadening its impact in the addiction treatment space.
Market Position and Competitive Landscape
Operating within the pharmaceutical industry, Indivior occupies a specialized niche focused on addiction and mental health treatments. The company distinguishes itself through its commitment to evidence-based solutions and its ability to address both the physical and psychological dimensions of addiction. In a competitive landscape that includes other pharmaceutical firms targeting SUD, Indivior's emphasis on innovation, regulatory compliance, and global reach positions it as a key player. Its products are tailored to meet the urgent needs of healthcare providers and patients, offering life-saving interventions and long-term management options.
Revenue Model and Operations
Indivior's revenue is primarily derived from the sale of its proprietary medications. The company operates in a highly regulated environment, ensuring that its products meet stringent safety and efficacy standards. Its global operations allow it to address diverse market needs, although it faces challenges such as navigating country-specific regulations and addressing the stigma associated with addiction treatment. Despite these hurdles, Indivior's focus on unmet medical needs and its robust product pipeline underscore its resilience and adaptability in a dynamic industry.
Significance in the Industry
Indivior plays a critical role in addressing the global opioid crisis, a public health emergency that claims thousands of lives annually. By offering rapid-acting and effective treatments like OPVEE, the company contributes to reducing opioid-related fatalities and improving patient outcomes. Its comprehensive approach to SUD, which includes addressing co-occurring mental health disorders, reflects a deep understanding of the complexities involved in addiction treatment. This positions Indivior as a trusted partner for healthcare providers and a vital resource for patients worldwide.
Commitment to Innovation
Indivior's dedication to research and development is evident in its expanding pipeline of product candidates. By leveraging clinical insights and pharmacological expertise, the company aims to develop treatments that not only address current challenges but also anticipate future needs in the addiction treatment landscape. This commitment to innovation ensures that Indivior remains at the forefront of its industry, continually enhancing its impact on public health.
Indivior PLC announced during its Capital Markets Day that the peak annual net revenue potential for SUBLOCADE has been increased to over $1.5 billion. The company is targeting a net revenue run rate of $1 billion by the end of 2025, bolstered by its focus on the Organized Health Systems channel. Indivior expects strong net revenue growth and operating margin expansion, with a disciplined capital allocation approach and plans for a NASDAQ listing in Spring 2023.
Indivior announced its acquisition of Opiant Pharmaceuticals for $20 per share, totaling approximately $145 million, with additional contingent payments of up to $8 per share depending on revenue milestones of OPNT003, Opiant's opioid overdose treatment. This strategic acquisition aims to enhance Indivior's position in addiction treatment and is expected to be accretive to earnings after the second year post-launch of OPNT003, which could generate annual revenues of $150-$250 million. The transaction is subject to regulatory approvals and is anticipated to close in Q1 2023.
Indivior PLC reported its financial results for Q3 2022, indicating continued efforts to address substance use disorders. The company's revenue growth is supported by a robust portfolio of opioid use disorder treatments. It aims to expand into additional chronic conditions and mental health areas. Indivior is dedicated to providing evidence-based treatment on a global scale, with products available in 39 countries. For the period ending September 30, 2022, more detailed information can be found in the earnings release, investor presentation, and webcast available on their official website.
Indivior PLC announced that shareholders approved resolutions for an Additional U.S. Listing on a major stock exchange and a 5:1 share consolidation, effective October 10, 2022. The goal is to meet minimum share price thresholds required for listing, enhancing visibility in its largest market. The U.S. Listing is anticipated to become effective in Spring 2023, with the Board assessing whether to list on the New York Stock Exchange or NASDAQ. Indivior will maintain its premium listing on the London Stock Exchange and is part of the FTSE 250 index.
Indivior PLC (LON: INDV) announced its participation in several upcoming investor healthcare events. CEO Mark Crossley will host meetings at the Morgan Stanley 20th Annual Global Healthcare Conference in New York on September 12, followed by appearances at the Bank of America Global Healthcare Conference in London on September 15-16, and a virtual fireside chat in the Jefferies Global Healthcare Fireside Chat Series on September 21. Investors can view presentations through provided webcast links. Indivior focuses on developing treatments for substance use disorders.
Indivior PLC (LON: INDV) observes September as National Recovery Month, emphasizing the importance of addressing substance use disorder (SUD) through evidence-based treatment. Recent data from the CDC reveals over 104,000 overdose deaths in the past year, highlighting the epidemic nature of SUD. Indivior's leadership stresses the need for stigma reduction and increased access to treatment. Currently, only 13.4% of individuals who could benefit from medication for opioid use disorder (MOUD) receive it. The company aims to transform global perceptions of addiction and improve access to treatments.
Indivior announced an analysis published in Drug and Alcohol Dependence Reports assessing the distribution patterns of buprenorphine extended-release (BUP-XR) for treating opioid use disorder (OUD) across various organized health systems (OHS) in the U.S., from July 2019 to July 2020. The study revealed that while BUP-XR access is increasing, significant barriers persist across different OHS subtypes, including Integrated Delivery Networks, Veterans Health Administration, Criminal Justice System, and Indian Health Services. Efforts to integrate OUD treatment into routine care are emphasized as crucial for improving access.
Indivior PLC (LON: INDV) reported its financial results for the period ending June 30, 2022. The company continues to focus on developing treatments for substance use disorders, with a pipeline that aims to address related chronic conditions. Earnings and investor presentation details are available on their website. The live webcast presentation hosted by CEO Mark Crossley is scheduled for July 28 at 1:00 PM BST. Indivior employs over 900 individuals globally and offers products in over 40 countries.
Indivior PLC has appointed Nina DeLorenzo as the new Chief Global Impact Officer, effective June 16, 2022. DeLorenzo will be part of the Executive Committee and will oversee corporate affairs, focusing on public and government relations, communications, and Environmental, Social, and Governance (ESG) initiatives. Her role aims to enhance the company's impact on patients and communities amidst a significant public health crisis.
With over 20 years of experience, DeLorenzo previously held senior roles at Emergent BioSolutions, Sanofi, AbbVie, and Pfizer.
Indivior PLC (LON: INDV) announced the acceptance of seven abstracts for presentation at the 84th Annual Scientific Meeting of the College on Problems of Drug Dependence, held June 11-15, 2022, in Minneapolis, MN. Key presentations will include a modeling study on buprenorphine-fentanyl interaction and its effects on respiratory depression, insights on long-term recovery from opioid use disorder (OUD), motivations for buprenorphine misuse, and Phase 1 clinical data on INDV-2000, a non-opioid medication for OUD. The data aims to enhance understanding of OUD treatment and recovery challenges.
FAQ
What is the market cap of INVVY (INVVY)?
What does Indivior PLC specialize in?
How does Indivior generate revenue?
What is OPVEE, and how is it used?
What makes Indivior unique in its industry?
What challenges does Indivior face in its market?
What is Indivior's approach to addressing the opioid crisis?
Does Indivior operate globally?
What other conditions does Indivior aim to treat beyond opioid addiction?
Who are Indivior's primary customers?
What role does evidence-based medicine play in Indivior's operations?
